4 Dose Modifications
If severe adverse reactions or laboratory abnormalities develop during combination
PEGASYS/
COPEGUS therapy, the dose should be modified until the adverse reactions abate. If intolerance persists after dose
adjustment, PEGASYS/COPEGUS therapy should be discontinued. Table 3, Table 4, Table 5, and Table 6 provide guidelines for dose modifications and discontinuation of PEGASYS/COPEGUS based on laboratory
abnormalities, patient’s depression status, and cardiac status.